Fetoscopic Surgery for Spina Bifida
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the feasibility of a fetoscopic surgical technique for antenatal correction of fetal myelomeningocele. Two surgical approaches will be utilized. The percutaneous approach will be offered to participants with a posterior placenta. The laparotomy/uterine exteriorization approach will be offered to participants regardless of placental location.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Fetoscopy, Fetoscopic surgery, Percutaneous endoscopic correction, Minimally invasive fetoscopic repair for Spina Bifida?
Research shows that minimally invasive fetoscopic surgery for spina bifida can improve neurological outcomes for babies and reduce the need for postnatal surgery, while also minimizing risks to the mother compared to open fetal surgery. The fetoscopic approach is evolving, with improvements in delivery outcomes and potential benefits similar to open surgery.12345
Is fetoscopic surgery for spina bifida generally safe for humans?
Fetoscopic surgery for spina bifida is designed to minimize risks to the mother compared to open fetal surgery, with careful management to ensure safety for both mother and fetus. Studies have shown that with proper anesthetic management and surgical techniques, risks such as preterm birth, anesthesia complications, and maternal trauma can be reduced.16789
How is fetoscopic surgery for spina bifida different from other treatments?
Fetoscopic surgery for spina bifida is a minimally invasive procedure that aims to repair the condition before birth, reducing the need for postnatal neurosurgery and minimizing risks to the mother compared to traditional open fetal surgery. This approach avoids large incisions, leading to a quicker recovery for the mother and potentially better neurological outcomes for the baby.123910
Research Team
Ruben Quintero, MD
Principal Investigator
Wellington Regional Medical Center
Ramen Chmait, MD
Principal Investigator
University of Southern California/ Huntington Memorial Hospital
Eligibility Criteria
This trial is for pregnant women over 18 with a fetus diagnosed with myelomeningocele, between 19-27 weeks' gestation. They must be able to stay near Wellington or Pasadena for the pregnancy and delivery, and return for follow-ups. Exclusions include multiple pregnancies, certain health conditions like HIV/Hepatitis-B, obesity (BMI of 35+), nickel allergy, pregestational diabetes, uterine anomalies, previous early deliveries.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo fetoscopic surgical correction of myelomeningocele using either laparotomy or percutaneous techniques
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Fetoscopy (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
USFetus
Lead Sponsor
Wellington Hospital
Collaborator
University of Southern California
Collaborator
Dr. Samir A.
University of Southern California
Chief Executive Officer since 2024
PhD in Molecular Biology from the University of Southern California
Dr. Chung
University of Southern California
Chief Medical Officer since 2016
MD from UC San Diego